Pseudomonadales

Shionogi Announces In Vitro and Real-World Data Presented at ECCMID 2021 Demonstrating Activity of cefiderocol Against Critical Priority Gram-negative Bacterial Pathogens

Retrieved on: 
Thursday, July 8, 2021

Cefiderocol also demonstrated broad activity against the isolates resistant to recently approved beta-lactam / beta-lactamase inhibitor combinations.

Key Points: 
  • Cefiderocol also demonstrated broad activity against the isolates resistant to recently approved beta-lactam / beta-lactamase inhibitor combinations.
  • Carbapenem-resistant A. baumannii (n=96; 40.5%) and carbapenem-resistant P. aeruginosa (n=78; 32.9%) were the most common pathogens.
  • Activity of Cefiderocol and Comparators against European Isolates of Pseudomonas aeruginosa, Acinetobacter baumannii-calcoaceticus species complex, and Stenotrophomonas maltophilia, including Carbapenem-Resistant Isolates.
  • The CARBAR part 1 study: a pooled analysis of the epidemiology data for UK, France and Spain: Bacterial susceptibility & resistance.

BiomX to Present Preclinical Results with BX004 in Cystic Fibrosis at the 44th European Cystic Fibrosis Conference

Retrieved on: 
Wednesday, June 9, 2021

BiomX Inc. (NYSE American: PHGE) (BiomX or the Company), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that preclinical results with BX004 in Cystic Fibrosis (CF) will be presented at the 44th European Cystic Fibrosis Conference (ECFS).

Key Points: 
  • BiomX Inc. (NYSE American: PHGE) (BiomX or the Company), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that preclinical results with BX004 in Cystic Fibrosis (CF) will be presented at the 44th European Cystic Fibrosis Conference (ECFS).
  • In vitro results demonstrate that BiomXs phage cocktail, BX004, was able to penetrate biofilm and was efficacious in significantly reducing bacterial levels of Pseudomonas aeruginosa encased in biofilm, relative to two different antibiotics.
  • Encouraged by these promising preclinical results, we look forward to advancing BX004 in CF to a Phase 1b/2a trial with results from Part 1 expected in the first quarter of 2022.
  • This press release contains express or implied forward-looking statements within the meaning of the safe harbor provisions of the U.S.

New, biological, and safer soaps

Retrieved on: 
Wednesday, May 19, 2021

Biosurfactants, produced by bacteria, are safer and can replace synthetic surfactants.\nRhamnolipid molecules are some of the safest surfactants known and are particularly attractive, thanks to their biodegradability, minimal toxicity, and amenability to be produced from industrial waste.

Key Points: 
  • Biosurfactants, produced by bacteria, are safer and can replace synthetic surfactants.\nRhamnolipid molecules are some of the safest surfactants known and are particularly attractive, thanks to their biodegradability, minimal toxicity, and amenability to be produced from industrial waste.
  • They are made using Pseudomonas aeruginosa, a pathogenic bacterium harmful to humans.\n"If we want to fully gain the benefits of rhamnolipids, we need to grow these pathogenic bacteria on a huge scale.
  • And because that\'s a health risk, the industry is looking for alternatives," explained Professor Gauthier.
  • The INRS community includes more than 1,500 students, postdoctoral fellows, faculty members, and staff.\n'

Armata Pharmaceuticals to Present at the Oppenheimer 31st Annual Healthcare Conference

Retrieved on: 
Tuesday, March 16, 2021

MARINA DEL REY, Calif., March 16, 2021 /PRNewswire/ --Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the Company will participate in the Oppenheimer 31st Annual Healthcare Conference taking place virtually March 16-18, 2021.

Key Points: 
  • MARINA DEL REY, Calif., March 16, 2021 /PRNewswire/ --Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the Company will participate in the Oppenheimer 31st Annual Healthcare Conference taking place virtually March 16-18, 2021.
  • Management is scheduled to present at 3:10pm ET on Wednesday, March 17.
  • Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens.
  • Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.

Results Published in Study Show MolecuLight Fluorescence Point-of-Care Imaging Detected Pseudomonas Aeruginosa (PA) in Wounds with a PPV of 93%

Retrieved on: 
Tuesday, March 2, 2021

Pseudomonas aeruginosa (PA) is a common bacterial pathogen in chronic wounds known for its propensity to form biofilms and evade conventional treatment methods.

Key Points: 
  • Pseudomonas aeruginosa (PA) is a common bacterial pathogen in chronic wounds known for its propensity to form biofilms and evade conventional treatment methods.
  • PA in wounds is associated with rapid wound deterioration2, higher rates of skin graft failure3, and higher rates of sepsis4.
  • Results from this clinician-directed study show that fluorescence imaging using the MolecuLight i:X can rapidly detect PA in chronic wounds.
  • Results of this analysis reveal that the cyan fluorescence detected in MolecuLight i:X images was predictive of PA in 93% of study wounds, yet less than 20% of the wounds exhibited the 'classic' symptoms of Pseudomonas.

Results Published in Study Show MolecuLight Fluorescence Point-of-Care Imaging Detected Pseudomonas Aeruginosa (PA) in Wounds with a PPV of 93%

Retrieved on: 
Tuesday, March 2, 2021

Pseudomonas aeruginosa (PA) is a common bacterial pathogen in chronic wounds known for its propensity to form biofilms and evade conventional treatment methods.

Key Points: 
  • Pseudomonas aeruginosa (PA) is a common bacterial pathogen in chronic wounds known for its propensity to form biofilms and evade conventional treatment methods.
  • PA in wounds is associated with rapid wound deterioration2, higher rates of skin graft failure3, and higher rates of sepsis4.
  • Results from this clinician-directed study show that fluorescence imaging using the MolecuLight i:X can rapidly detect PA in chronic wounds.
  • Results of this analysis reveal that the cyan fluorescence detected in MolecuLight i:X images was predictive of PA in 93% of study wounds, yet less than 20% of the wounds exhibited the 'classic' symptoms of Pseudomonas.

Polyphor Receives Approval to Start First-in-Human Clinical Trial of Inhaled Antibiotic Murepavadin

Retrieved on: 
Tuesday, December 22, 2020

The Phase I study is part of the clinical development plan exploring the inhaled formulation of murepavadin to treat Pseudomonas aeruginosa infections in people with cystic fibrosis, including resistant bacterial strains.

Key Points: 
  • The Phase I study is part of the clinical development plan exploring the inhaled formulation of murepavadin to treat Pseudomonas aeruginosa infections in people with cystic fibrosis, including resistant bacterial strains.
  • The safety, tolerability, and pharmacokinetic study is using eFlow Technology nebulizer (PARI Pharma GmbH) to administer murepavadin Inhalation Solution (MIS) in healthy volunteers.
  • Polyphors inhaled murepavadin is currently being developed as a precision antibiotic specifically for the treatment of chronic Pseudomonas aeruginosa infections in people with CF.
  • Based on the data of the inhaled murepavadin preclinical program suggesting significantly higher safety margins (at least 5-10 times) versus the intravenous formulation, Polyphor is initiating a clinical development program in CF.

CF Foundation Awards Up to $3.3M to Polyphor for Inhaled Version of Antibiotic to Treat Pseudomonas

Retrieved on: 
Tuesday, November 24, 2020

Today, the Cystic Fibrosis Foundation announced it has awarded up to $3.3 million to Polyphor AG to develop an inhaled version of murepavadin, an antibiotic that targets multi-drug resistant Pseudomonas aeruginosa infections in people with cystic fibrosis.

Key Points: 
  • Today, the Cystic Fibrosis Foundation announced it has awarded up to $3.3 million to Polyphor AG to develop an inhaled version of murepavadin, an antibiotic that targets multi-drug resistant Pseudomonas aeruginosa infections in people with cystic fibrosis.
  • An inhaled version could make it easier for someone with a Pseudomonas infection to take the drug from home.
  • In addition, the drug, which targets the outer membrane of bacteria, specifically focuses on Pseudomonas, which might have certain advantages over broad-spectrum antibiotics.
  • The Foundation funds more CF research than any other organization, and nearly every CF drug available today was made possible because of Foundation support.

Pseudomonas Aeruginosa Pneumonia Pipeline Review, H2 2020 - Therapeutic Assessment of 4 Companies & 7 Drug Profiles - ResearchAndMarkets.com

Retrieved on: 
Monday, November 2, 2020

The "Pseudomonas aeruginosa Pneumonia - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Pseudomonas aeruginosa Pneumonia - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Pseudomonas aeruginosa Pneumonia - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Pseudomonas aeruginosa Pneumonia (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Pseudomonas aeruginosa Pneumonia (Infectious Disease) pipeline guide also reviews key players involved in therapeutic development for Pseudomonas aeruginosa Pneumonia and features dormant and discontinued projects.
  • Formulate corrective measures for pipeline projects by understanding Pseudomonas aeruginosa Pneumonia (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Armata Pharmaceuticals Announces Clearance of Investigational New Drug (IND) Application to Initiate Phase 1b/2a Clinical Trial of Lead Candidate AP-PA02 in Pseudomonas aeruginosa Infections

Retrieved on: 
Thursday, October 15, 2020

to reflect the manner in which phage attack dangerous pathogens, will be our Company's first clinical trial to evaluate a phage-based therapy as a potential treatment for Pseudomonas aeruginosa airway infections.

Key Points: 
  • to reflect the manner in which phage attack dangerous pathogens, will be our Company's first clinical trial to evaluate a phage-based therapy as a potential treatment for Pseudomonas aeruginosa airway infections.
  • Barring worsening COVID-19 conditions, Armata expects to initiate the SAD cohort by the end of this year.
  • Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens.
  • Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.